10-Q: Cytek Biosciences Q1 2026 Financial Results

Cytek Biosciences reported Q1 2026 revenue of $44.1 million, a 6% year-over-year increase, alongside a net loss of $18.9 million.

Summary

• Total revenue for the first quarter of 2026 was $44.1 million, up 6% from $41.5 million in Q1 2025.
• Product revenue grew 2% to $28.8 million, while service revenue increased 15% to $15.4 million.
• Net loss for the quarter was $18.9 million, compared to a net loss of $11.4 million in the same period last year.
• Operating expenses rose to $39.7 million from $35.1 million, driven primarily by higher general and administrative costs.
• Cash and cash equivalents totaled $65.7 million as of March 31, 2026.

Sentiment

Score: 4

Explanation: StockSavvy.ai views this as a cautious report, reflecting increased operational costs and a widening net loss, despite modest revenue growth.

Positives

• Total revenue increased by 6% year-over-year.
• Service revenue showed strong growth of 15%, indicating an expanding installed base.
• The company maintains a solid liquidity position with $262.2 million in combined cash, cash equivalents, and short-term investments.

Negatives

• Net loss widened to $18.9 million from $11.4 million in the prior year quarter.
• Gross margin declined to 48% from 49% due to service costs growing faster than service revenue.
• General and administrative expenses increased significantly by 43% to $18.5 million, largely due to litigation-related costs and bad debt reserves.

Risks

• Ongoing litigation with Beckman Coulter regarding patent infringement.
• Dependence on a limited number of product offerings and single-source suppliers for key components.
• Exposure to international trade policies, tariffs, and export controls, particularly concerning China.
• Potential for further volatility in operating results due to lengthy sales cycles and macroeconomic conditions.
• Risks associated with data privacy and security, including a security incident reported in November 2025.

Future Outlook

The company expects expenses to increase substantially as it continues to invest in commercial infrastructure, research and development, and geographic expansion. Management believes existing cash and cash flows will be sufficient to meet needs for at least the next 12 months.

Management Comments

• Management noted that the increase in general and administrative expenses was primarily due to higher litigation-related expenses, outside consulting expenses, and bad debt reserves.
• Management highlighted that the company is focused on controlling general and administrative expenses, though they may increase in absolute dollars to support business growth.

Industry Context

StockSavvy.ai notes that Cytek is navigating a challenging macroeconomic environment for life sciences tools, characterized by high interest rates and a difficult fundraising environment for small biotech customers, which has extended sales cycles across the industry.

Comparison to Industry Standards

• Cytek's gross margin of 48% remains competitive within the life sciences instrumentation sector, though it faces pressure from rising service overheads.
• The company's reliance on academic and government funding is consistent with peers like Bio-Rad and Agilent, making it sensitive to NIH budget fluctuations.

Legal Proceedings

• Ongoing patent infringement lawsuit filed by Beckman Coulter, Inc. in August 2024; trial scheduled for August 17, 2026.

Stakeholder Impact

• Shareholders may face potential dilution if the company raises additional capital.
• Customers may experience potential supply chain constraints if the company cannot accurately forecast demand.

Next Steps

• Continue to defend against the Beckman Coulter patent infringement lawsuit with a trial scheduled for August 17, 2026.
• Continue investment in research and development and commercial infrastructure.
• Monitor and evaluate the impact of the One Big Beautiful Bill Act (OBBBA) on tax assets and liabilities.

Key Dates

Recommendation

The company is in a growth phase but is currently facing significant headwinds, including rising operating costs, ongoing litigation, and a widening net loss, warranting a cautious hold until profitability trends improve.

Keywords

Cytek Biosciences, CTKB, flow cytometry, Full Spectrum Profiling, cell analysis, biotechnology, 10-Q